Table 5. Multivariate analysis of risk factors for progression-free survival and overall survival (n = 59).
| Progression-free survival | ||
|---|---|---|
| Hazard ratio (95% CI) | P-value | |
| LDH > (1 × ULN) | 6.21 (2.04–16.02) | < 0.001 |
| Non-CR after front-line treatment | 4.23 (1.55–11.51) | 0.005 |
| Serum albumin < 3.5 g/dL | 2.69 (1.40–5.17) | 0.003 |
| Platelets < 130 × 109/L | 0.93 (0.35–2.48) | 0.893 |
| Serum β2-microglobulin > 5.5 mg/L | 1.81 (0.77–4.24) | 0.173 |
| Overall survival | ||
| Hazard ratio (95% CI) | P-Value | |
| LDH > (1 × ULN) | 8.03 (2.11–30.48) | 0.002 |
| Non-CR after front-line treatment | 8.31 (2.20–31.33) | 0.002 |
| Serum albumin < 3.5 g/dL | 3.25 (1.42–7.42) | 0.005 |
| Serum β2-microglobulin > 5.5 mg/L | 2.59 (0.97–6.91) | 0.058 |
| Platelets < 130 × 109/L | 1.42 (0.37–5.35) | 0.604 |
| del(17p13) | 0.88 (0.35–2.18) | 0.788 |
Abbreviations: LDH, lactate dehydrogenase; ULN, upper limit of normal value; CR, complete response; ASCT, autologous stem cell transplant.